Editorial Comment to Impact of alternative antiandrogen therapy for Japanese prostate cancer patients in the era of new hormonal therapy.

Nakata I et al i . evaluated the prognostic significance of alternative antiandrogen therapy, and compared prostate-specific antigen response rates for abiraterone and enzalutamide between responders and non-responders to alternative antiandrogen therapy.[1] They found that alternative antiandrogen therapy was effective in 56.7% of patients and these responders had significantly better overall survival than non-responders, and that cross-resistance between alternative antiandrogen therapy and new hormonal therapies was not detected. Based on these findings, they concluded that alternative antiandrogen therapy might still be of therapeutic value for Japanese patients with advanced prostate cancer in the era of new hormonal therapy. To conclude that alternative antiandrogen therapy is of therapeutic value, the outcomes must be compared between the patients with or without alternative antiandrogen therapy. [Extracted from the article]